https://doi.org/10.3350/cmh.2023.0426

Supplementary Table 7. Clinical outcomes among NAFLD participants, by median study year

	Studies	N	≤Median study year	Studies	N	>Median study year	*P*–value
All-cause mortality	21	25,013	17.29 (13.33–21.26)	16	488,396	11.36 (6.46–16.25)	0.065
Liver-related mortality	13	18,781	3.12 (1.37–4.87)	13	99,224	3.28 (0.13–6.44)	0.92
Cardiovascular-related mortality	11	17,970	6.83 (4.39–9.27)	11	98,686	1.68 (0.82–2.55)	<0.0001
Non-liver cancer related mortality	11	18,416	4.55 (3.21–5.90)	11	98,533	1.76 (0.99–2.53)	<0.0001
All liver events	22	61,853	23.23 (9.31–37.15)	18	542,054	25.56 (9.82–41.30)	0.83
Cirrhosis	13	44,025	8.50 (2.57–14.44)	8	265,010	14.65 (6.20–23.11)	0.17
Hepatocellular carcinoma	17	57,017	3.30 (0.00–6.68)	13	279,169	3.71 (0.70–6.72)	0.85
Liver transplant	6	1,914	19.49 (0.00–60.86)	4	1,589	1.77 (0.00–4.73)	0.27
Decompensated cirrhosis	8	2,559	6.45 (0.14–12.77)	8	129,424	17.66 (7.97–27.35)	0.022
Ascites	7	2,285	2.73 (0.86–4.61)	6	2,479	11.32 (3.82–18.81)	0.030
Varices/variceal bleeding	6	2,297	4.74 (1.04–8.44)	5	2,021	4.88 (2.25–7.51)	0.95
Encephalopathy	5	2,007	1.86 (0.65–3.07)	3	1,455	4.56 (0.00–9.58)	0.31
Cardiovascular events	11	28,685	14.09 (6.66–21.51)	8	159,683	43.55 (0.00–94.91)	0.18
Coronary artery disease/congestive heart failure	4	26,677	12.33 (3.90–20.75)	4	11,029	71.15 (72.1–141.58)	0.10
Myocardial infarction	6	63,826	3.27 (1.49–5.05)	3	121,348	17.48 (0.00–48.57)	0.37
Stroke	5	26,747	4.47 (2.00–6.94)	5	121,824	13.85 (0.00–32.45)	0.33
Diabetes mellitus	12	9,431	19.36 (13.82–24.89)	12	30,058	19.43 (13.26–25.61)	0.99
Dyslipidemia/hyperlipidemia	4	4,798	25.47 (0.33–50.61)	3	4,751	27.68 (10.17–45.19)	0.8875
Hypertension	6	1,374	30.50 (11.48–49.52)	6	4,217	21.58 (7.82–35.34)	0.4563
Non-liver cancer	8	15,657	11.40 (9.03–13.78)	3	13,586	7.34 (6.76–7.93)	0.0012
Renal impairment	3	53,762	12.23 (6.98–17.49)	3	277,110	49.86 (0.00–135.8)	0.3918

NAFLD, non-alcoholic fatty liver disease.